Abstract

474O - Efficacy and safety of first-line durvalumab (D) ± tremelimumab (T) vs chemotherapy (CT) in Asian patients with metastatic NSCLC: Results from MYSTIC

Full Text
Published version (Free)

Talk to us

Join us for a 30 min session where you can share your feedback and ask us any queries you have

Schedule a call

Similar Papers

Paper Title
Journal
Date
Author
1542P - Safety of lorlatinib in subgroups of patients from a phase I/II trial
E Felip ... G Peltz
Annals of Oncology | VOL. 30
E Felip, et. al.E Felip ... G Peltz
01 Oct 2019
LBA19 - Updated overall survival (OS) from extended follow up in ARCHER 1050: A randomized phase III study comparing dacomitinib with gefitinib as first-line therapy for patients (pts) with EGFR mutations
J Corral ... A Pluzanski
Annals of Oncology | VOL. 30
J Corral, et. al.J Corral ... A Pluzanski
01 Nov 2019
1482O - Outcomes with pembrolizumab (pembro) monotherapy in patients (pts) with PD-L1–positive NSCLC with brain metastases: Pooled analysis of KEYNOTE-001, -010, -024, and -042
M Satouchi ... T.S.K Mok
Annals of Oncology | VOL. 30
M Satouchi, et. al.M Satouchi ... T.S.K Mok
01 Oct 2019
1459PD - Efficacy of durvalumab in patients with stage III NSCLC who experience pneumonitis (PACIFIC)
P.A Dennis ... M Özgüroğlu
Annals of Oncology | VOL. 30
P.A Dennis, et. al.P.A Dennis ... M Özgüroğlu
01 Oct 2019
View more papers

More From: Annals of Oncology

Paper Title
Journal
Date
Author
Abemaciclib plus a nonsteroidal aromatase inhibitor as initial therapy for HR+, HER2- advanced breast cancer: Final overall survival results of MONARCH 3
M.P Goetz ... S.R.D Johnston
Annals of Oncology | VOL. -
M.P Goetz, et. al.M.P Goetz ... S.R.D Johnston
01 May 2024
Overcoming barriers in biomarker testing. Letter to the Editor regarding: “ESMO study on the availability and accessibility of biomolecular technologies in oncology in Europe”, by A. Bayle et al.
J García-Foncillas ... A Stenzinger
Annals of Oncology | VOL. -
J García-Foncillas, et. al.J García-Foncillas ... A Stenzinger
01 May 2024
Table of Contents
-
Annals of Oncology | VOL. 35
--
01 May 2024
VP2-2024: Fuzuloparib with or without apatinib in HER2- metastatic breast cancer (mBC) patients (pts) with germline BRCA1/2 mutations (gBRCA1/2m): A randomized phase III trial
H Li ... E Song
Annals of Oncology | VOL. -
H Li, et. al.H Li ... E Song
01 May 2024
View more papers